Emerging Biotech
Drive Launch Success
Go to market more effectively with a well-orchestrated launch.
2 x
projected increase in FDA approvals for cell and gene therapies by the end of the decade
36 %
of drugs failed to meet market expectations in the first year
44 %
of HCPs are satisfied with pharma engagement at launch
40 %
faster treatment adoption with pre-launch HCP scientific engagement
Sources: Biopharma Launch Challenge | Veeva
Blog
Launch Challenge: Closing the Gap from Drug Pipeline to Patient
Discover how biopharmas can launch an unprecedented peak of new products by scaling smarter, not larger, through a connected ecosystem powered by AI.
“With Veeva as our trusted partner, we accelerated launch readiness and equipped new sales, medical, and marketing teams with the digital tools they need.”
Christopher Mutz
Chief Commercial Officer & Head of Rare Disease, ANI Pharmaceuticals
“Technology is a key enabler for every step of a product launch. Building comprehensive IT capabilities within the complex and regulated pharma industry while meeting strict deadlines is possible with a readily available platform like Veeva that covers the full technology stack, from clinical to commercial.”
Joseph Bejjani
CIO at Idorsia
“Link Medical Insights has been very impactful to our medical affairs strategy. We recently received FDA approval so it was a very critical time to gain timely insights.”
Kristina M. Kipp
Regional Medical Director, BridgeBio
Launch solutions
for emerging biotech
Learn why hundreds of pre-commerial companies rely on Veeva to plan and execute their launch.